Tag Archives: Boehringer Ingelheim’s SYNCHRONIZE-2 trial reports up to 13.1% average weight loss with investigational survodutide in adults with type 2 diabetes

Boehringer Ingelheim reports Phase III SYNCHRONIZE-2 data showing survodutide weight reduction and glycemic improvements in adults with obesity and type 2 diabetes

Posted on 2, October 2026 by EuropaWire PR Editors

The 76-week trial met its co-primary endpoints, with up to 13.1% average weight loss using the efficacy estimand and improvements in HbA1c, waist circumference and insulin sensitivity. IN BRIEFKEY TAKEAWAYSFAQs Boehringer Ingelheim reported positive Phase III SYNCHRONIZE-2 results for investigational … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech

Tagged BI 456906, Boehringer Ingelheim, Boehringer Ingelheim presents survodutide Phase III results in obesity or overweight with type 2 diabetes, Boehringer Ingelheim’s SYNCHRONIZE-2 trial reports up to 13.1% average weight loss with investigational survodutide in adults with type 2 diabetes, cardiometabolic health, Dual Agonist, EASD, European Association for the Study of Diabetes, Germany, GLP-1, glucagon receptor, glycemic control, HbA1c, Ingelheim, insulin sensitivity, LIVERAGE, LIVERAGE-Cirrhosis, MASH, Obesity, overweight, Phase III SYNCHRONIZE-2 data show survodutide met co-primary weight-loss endpoints and improved glycemic markers, Sean Wharton, Shashank Deshpande, Survodutide, SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-2 findings show weight reduction alongside HbA1c and insulin-sensitivity improvements with survodutide, SYNCHRONIZE-CVOT, SYNCHRONIZE-T2D, T2D, The New England Journal of Medicine, type 2 diabetes, Zealand Pharma